Phase I trial of dose-escalating metronomic temozolomide plus bevacizumab and bortezomib for patients with recurrent glioblastoma

Phase II trial of irinotecan and metronomic temozolomide in patients with recurrent glioblastoma

(2016) Gaspar Reynés et al.   ANTI-CANCER DRUGS

A phase II trial evaluating the effects and intra-tumoral penetration of bortezomib in patients with recurrent malignant gliomas

(2016) Jeffrey J. Raizer et al.   JOURNAL OF NEURO-ONCOLOGY

Efficacy of low dose temozolomide in combination with bortezomib in U87 glioma cells: a flow cytometric analysis

(2015) Panagiotis J. Vlachostergios et al.   Archives of Medical Science

The role of cytotoxic chemotherapy in the management of progressive glioblastoma

(2014) Jeffrey J. Olson et al.   JOURNAL OF NEURO-ONCOLOGY

The role of targeted therapies in the management of progressive glioblastoma

(2014) Jeffrey J. Olson et al.   JOURNAL OF NEURO-ONCOLOGY

Bortezomib Downregulates MGMT Expression in T98G Glioblastoma Cells

(2013) Panagiotis J. Vlachostergios et al.   CELLULAR AND MOLECULAR NEUROBIOLOGY

Bortezomib overcomes MGMT-related resistance of glioblastoma cell lines to temozolomide in a schedule-dependent manner

(2013) Panagiotis J. Vlachostergios et al.   INVESTIGATIONAL NEW DRUGS

Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis

(2013) Daniela A. Bota et al.   JOURNAL OF NEUROSURGERY

Severe sustained cholestatic hepatitis following temozolomide in a patient with glioblastoma multiforme: case study and review of data from the FDA adverse event reporting system

(2012) G. Sarganas et al.   NEURO-ONCOLOGY

Bortezomib Primes Glioblastoma, Including Glioblastoma Stem Cells, for TRAIL by Increasing tBid Stability and Mitochondrial Apoptosis

(2011) T. Unterkircher et al.   CLINICAL CANCER RESEARCH

Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status

(2011) Eric Van Cutsem et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study

(2011) B. B. Friday et al.   NEURO-ONCOLOGY

Neural stem/progenitors and glioma stem-like cells have differential sensitivity to chemotherapy

(2011) X. Gong et al.   NEUROLOGY

Survival of Patients with Newly Diagnosed Glioblastoma Treated with Radiation and Temozolomide in Research Studies in the United States

(2010) S. A. Grossman et al.   CLINICAL CANCER RESEARCH

Phase II Trial of Continuous Dose-Intense Temozolomide in Recurrent Malignant Glioma: RESCUE Study

(2010) James R. Perry et al.   JOURNAL OF CLINICAL ONCOLOGY

Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

(2010) Patrick Y. Wen et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma

(2010) Surasak Phuphanich et al.   JOURNAL OF NEURO-ONCOLOGY

The effects of proteasome inhibitor bortezomib on a P-gp positive leukemia cell line K562/A02

(2009) S. LÜ et al.   International Journal of Laboratory Hematology

Randomized Phase II Trial of Chemoradiotherapy Followed by Either Dose-Dense or Metronomic Temozolomide for Newly Diagnosed Glioblastoma

(2009) Jennifer L. Clarke et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma

(2009) Henry S. Friedman et al.   JOURNAL OF CLINICAL ONCOLOGY

Salvage therapy with single agent bevacizumab for recurrent glioblastoma

(2009) Marc C. Chamberlain et al.   JOURNAL OF NEURO-ONCOLOGY

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

(2009) Roger Stupp et al.   LANCET ONCOLOGY

FDA Drug Approval Summary: Bevacizumab (Avastin(R)) as Treatment of Recurrent Glioblastoma Multiforme

(2009) M. H. Cohen et al.   ONCOLOGIST

Phase I Trial Using Proteasome Inhibitor Bortezomib and Concurrent Temozolomide and Radiotherapy for Central Nervous System Malignancies

(2008) Gregory J. Kubicek et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma

(2008) Teri N. Kreisl et al.   JOURNAL OF CLINICAL ONCOLOGY